The Role of External Beam Radiation and Targeted Therapy in Thyroid Cancer

Seminars in Radiation Oncology

Volumn 22, Issue 3, 2012, Pages 254-262

  Brierley, James ^a   Sherman, Eric ^b,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; B RAF KINASE; COMBRETASTATIN A4 PHOSPHATE; DABRAFENIB; DOCETAXEL; DOXORUBICIN; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PACLITAXEL; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SORAFENIB; VEMURAFENIB;

ANAPLASTIC THYROID CANCER; ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; DIFFERENTIATED THYROID CANCER; DYSPHAGIA; ESOPHAGITIS; ESOPHAGUS STRICTURE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LARYNX EDEMA; MELANOMA; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PATIENT SELECTION; PHARYNGITIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SIGNAL TRANSDUCTION; THYROID CANCER; THYROID MEDULLARY CARCINOMA; TREATMENT FAILURE; TREATMENT PLANNING;

CARCINOMA, MEDULLARY; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; HUMANS; MOLECULAR TARGETED THERAPY; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; THYROID NEOPLASMS;

EID: 84862136723     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2012.03.010     Document Type: Review

References (81)

1. Vassilopoulou-Sellin R., Schultz P.N., Haynie T.P. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy. Cancer 1996, 78:493-501.
2. Coburn M.C., Wanebo H.J. Age correlates with increased frequency of high risk factors in elderly patients with thyroid cancer. Am J Surg 1995, 170:471-475.
3. Sheline G.E., Galante M., Lindsay S. Radiation therapy in the control of persistent thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 1966, 97:923-930.
4. Chow S.M., Law S.C., Mendenhall W.M., et al. Papillary thyroid carcinoma: Prognostic factors and the role of radioiodine and external radiotherapy. Int J Radiat Oncol Biol Phys 2002, 52:784-795.
5. Tubiana M., Haddad E., Schlumberger M., et al. External radiotherapy in thyroid cancers. Cancer 1985, 55(suppl9):2062-2071.
6. Simpson W.J. Radioiodine and radiotherapy in the management of thyroid cancers. Otolaryngol Clin North Am 1990, 23:509-521.
7. O'Connell M.E., A'Hern R.P., Harmer C.L. Results of external beam radiotherapy in differentiated thyroid carcinoma: A retrospective study from the Royal Marsden Hospital. Eur J Cancer 1994, 30A:733-739.
8. Sia M.A., Tsang R.W., Panzarella T., et al. Differentiated thyroid cancer with extrathyroidal extension: Prognosis and the role of external beam radiotherapy. J Thyroid Res 2010, Accessed May 6, 2010. http://www.hindawi.com/journals/jtr/2010/183461/.
9. Brierley J., Tsang R., Simpson W.J., et al. Medullary thyroid cancer-Analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 1996, 6:305-310.
10. Simpson W.J., Panzarella T., Carruthers J.S., et al. Papillary and follicular thyroid cancer: Impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 1988, 14:1063-1075.
11. Phlips P., Hanzen C., Andry G., et al. Postoperative irradiation for thyroid cancer. Eur J Surg Oncol 1993, 19:399-404.
12. Farahati J., Reiners C., Stuschke M., et al. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). Cancer 1996, 77:172-180.
13. Tsang R.W., Brierley J.D., Simpson W.J., et al. The effects of surgery, radioiodine and external radiation therapy on the clinical outcome of patients with differentiated thyroid cancer. Cancer 1998, 82:375-388.
14. Ford D., Giridharan S., McConkey C., et al. External beam radiotherapy in the management of differentiated thyroid cancer. Clin Oncol (R Coll Radiol) 2003, 15:337-341.
15. Kim T.H., Yang D.S., Jung K.Y., et al. Value of external irradiation for locally advanced papillary thyroid cancer. Int J Radiat Oncol Biol Phys 2003, 55:1006-1012.
16. Brierley J., Tsang R., Panzarella T., et al. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. Clin Endocrinol (Oxf) 2005, 63:418-427.
17. Keum K.C., Suh Y.G., Koom W.S., et al. The role of postoperative external-beam radiotherapy in the management of patients with papillary thyroid cancer invading the trachea. Int J Radiat Oncol Biol Phys 2006, 65:474-480.
18. Meadows K.M., Amdur R.J., Morris C.G., et al. External beam radiotherapy for differentiated thyroid cancer. Am J Otolaryngol 2006, 27:24-28.
19. Terezakis S.A., Lee K.S., Ghossein R.A., et al. Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-Kettering cancer center experience. Int J Radiat Oncol Biol Phys 2009, 73:795-801.
20. Schwartz D.L., Lobo M.J., Ang K.K., et al. Postoperative external beam radiotherapy for differentiated thyroid cancer: Outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys 2009, 74:1083-1091.
21. Cooper D.S., Doherty G.M., et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19:1167-1214. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer.
22. British Thyroid Association: Guidelines for the management of thyroid cancer in adults 2006, Royal College of Physicians, London, UK, 1-70.
23. Biermann M., Pixberg M., Riemann B., et al. Clinical outcomes of adjuvant external-beam radiotherapy for differentiated thyroid cancer-Results after 874 patient-years of follow-up in the MSDS-trial. Nuklearmedizin 2009, 48:89-98. quiz N15.
24. Azrif M., Slevin N.J., Sykes A.J., et al. Patterns of relapse following radiotherapy for differentiated thyroid cancer: Implication for target volume delineation. Radiother Oncol 2008, 89:105-113.
25. Wang W., Larson S.M., Tuttle R.M., et al. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 2001, 11:1169-1175.
26. Robbins R.J., Wan Q., Grewal R.K., et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-d-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006, 91:498-505.
27. Martinez S.R., Beal S.H., Chen A., et al. Adjuvant external beam radiation for medullary thyroid carcinoma. J Surg Oncol 2010, 102:175-178.
28. Fife K.M., Bower M., Harmer C.L. Medullary thyroid cancer: The role of radiotherapy in local control. Eur J Surg Oncol 1996, 22:588-591.
29. Mak A., Morrison W.H., Garden A. The value of postoperative radiotherapy for regional medullary carcinoma of the thyroid. Int J Radiat Oncol Biol Phys 1994, 30. A234.
30. Schwartz D.L., Rana V., Shaw S., et al. Postoperative radiotherapy for advanced medullary thyroid cancer-Local disease control in the modern era. Head Neck 2008, 30:883-888.
31. Kloos R.T., Eng C., et al. Medullary thyroid cancer: management guidelines of the American thyroid association. Thyroid 2009, 19:565-612. American Thyroid Association Guidelines Task force.
32. Goutsouliak V., Hay J.H. Anaplastic thyroid cancer in British Columbia 1985-1999: A population-based study. Clin Oncol (R Coll Radiol) 2005, 17:75-78.
33. Haigh P.I., Ituarte P.H., Wu H.S., et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 2001, 91:2335-2342.
34. Wang Y., Tsang R., Asa S., et al. Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. Cancer 2006, 107:1786-1792.
35. Haigh P.I. Anaplastic thyroid carcinoma. Curr Treat Options Oncol 2000, 1:353-357.
36. Kim J.H., Leeper R.D. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 1987, 60:2372-2375.
37. De Crevoisier R., Baudin E., Bachelot A., et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 2004, 60:1137-1143.
38. Brignardello E., Gallo M., Baldi I., et al. Anaplastic thyroid carcinoma: Clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years. Eur J Endocrinol 2007, 156:425-430.
39. Swaak-Kragten A.T., de Wilt J.H., Schmitz P.I., et al. Multimodality treatment for anaplastic thyroid carcinoma-Treatment outcome in 75 patients. Radiother Oncol 2009, 92:100-104.
40. Sherman E.J., Lim S.H., Ho A., et al. Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: A critical re-evaluation including uniform pathologic review. Radiother Oncol 2011, 101:425-430.
41. Sherman E.J., Lim S.H., Ho A.L., et al. Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: A critical re-evaluation including uniform pathologic review. Radiother Oncol 2011, 101:425-430.
42. Troch M., Koperek O., Scheuba C., et al. High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel. J Clin Endocrinol Metab 2010, 95:E54-E57.
43. Ain K.B., Egorin M.J., DeSimone P.A. Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase 2 trial using ninety-six-hour infusion. Collaborative anaplastic thyroid cancer health intervention trials (CATCHIT) group. Thyroid 2000, 10:587-594.
44. Nagaiah G., Fu P., Wasman J.K., et al. Phase II trial of sorafenib (bay 43-9006) in patients with advanced anaplastic carcinoma of the thyroid (ATC). J Clin Oncol 2009, 27. A6058 (suppl 15).
45. Ha H.T., Lee J.S., Urba S., et al. Phase II trial evaluating imatinib (I) in patients (pts) with anaplastic thyroid carcinoma (ATC). J Clin Oncol 27 2009, A6057 (suppl15).
46. Cohen E.E., Rosen L.S., Vokes E.E., et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol 2008, 26:4708-4713.
47. Sosa J.A., Elisei R., Jarzab B., et al. A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial. J Clin Oncol 2011, 29. A5502.
48. Brierley J.D., Tsang R.W. External beam radiation therapy for thyroid cancer. Endocrinol Metab Clin North Am 2008, 37:497-509.
49. Kim T.H., Chung K.W., Lee Y.J., et al. The effect of external beam radiotherapy volume on locoregional control in patients with locoregionally advanced or recurrent nonanaplastic thyroid cancer. Radiol Oncol 2010, 5:69.
50. Nutting C.M., Convery D.J., Cosgrove V.P., et al. Improvements in target coverage and reduced spinal cord irradiation using intensity-modulated radiotherapy (IMRT) in patients with carcinoma of the thyroid gland. Radiother Oncol 2001, 60:173-180.
51. Brierley J., Rumble R.B., Warde P., et al. The Role of IMRT in thyroid cancers Accessed April 4, 2012 Ontario, Canada, Cancer Care, 2011. http://www.cancercare.on.ca/toolbox/qualityguidelines/clin-program/radther/.
52. Pfister D.G., Fagin J.A. Refractory thyroid cancer: A paradigm shift in treatment is not far off. J Clin Oncol 2008, 26:4701-4704.
53. Kimura E.T., Nikiforova M.N., Zhu Z., et al. High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003, 63:1454-1457.
54. Fagin J.A. Genetics of papillary thyroid cancer initiation: Implications for therapy. Trans Am Clin Climatol Assoc 2005, 116:259-269. discussion 269-271.
55. Nikiforova M.N., Kimura E.T., Gandhi M., et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003, 88:5399-5404.
56. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
57. Ball D.W., Jin N., Rosen D.M., et al. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab 2007, 92:4712-4718.
58. Leboeuf R., Baumgartner J.E., Benezra M., et al. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab 2008, 93:2194-2201.
59. Lucas A.S., Cohen E.E., Cohen R.B., et al. Phase II study and tissue correlative studies of AZD6244 (ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma (IRPTC) and papillary thyroid carcinoma (PTC) with follicular elements. J Clin Oncol 2010, 28. A5536.
60. Ricarte-Filho J.C., Ryder M., Chitale D.A., et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 2009, 69:4885-4893.
61. Podsypanina K., Lee R.T., Politis C., et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci U S A 2001, 98:10320-10325.
62. Neshat M.S., Mellinghoff I.K., Tran C., et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001, 98:10314-10319.
63. Majumder P.K., Febbo P.G., Bikoff R., et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004, 10:594-601.
64. Hartford C.M., Ratain M.J. Rapamycin: Something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther 2007, 82:381-388.
65. Dhar D.K., Kubota H., Kotoh T., et al. Tumor vascularity predicts recurrence in differentiated thyroid carcinoma. Am J Surg 1998, 176:442-447.
66. Ishiwata T., Iino Y., Takei H., et al. Tumor angiogenesis as an independent prognostic indicator in human papillary thyroid carcinoma. Oncol Rep 1998, 5:1343-1348.
67. Soh E.Y., Duh Q.Y., Sobhi S.A., et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 1997, 82:3741-3747.
68. Viglietto G., Romano A., Manzo G., et al. Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Oncogene 1997, 15:2687-2698.
69. Bauer A.J., Terrell R., Doniparthi N.K., et al. Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. Thyroid 2002, 12:953-961.
70. Yu X.M., Lo C.Y., Lam A.K., et al. The potential clinical relevance of serum vascular endothelial growth factor (VEGF) and VEGF-C in recurrent papillary thyroid carcinoma. Surgery 2008, 144:934-940. discussion 940-941.
71. Bunone G., Vigneri P., Mariani L., et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 1999, 155:1967-1976.
72. Viglietto G., Maglione D., Rambaldi M., et al. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 1995, 11:1569-1579.
73. Klein M., Vignaud J.M., Hennequin V., et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 2001, 86:656-658.
74. Lennard C.M., Patel A., Wilson J., et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 2001, 129:552-558.
75. Gupta-Abramson V., Troxel A.B., Nellore A., et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008, 26:4714-4719.
76. Kloos R.T., Ringel M.D., Knopp M.V., et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009, 27:1675-1684.
77. Carr L.L., Mankoff D.A., Goulart B.H., et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010, 16:5260-5268.
78. Cohen E.E., Needles B.M., Cullen K.J., et al. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 2008, 26. A6025.
79. Bible K.C., Suman V.J., Molina J.R., et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: Results of a phase 2 consortium study. Lancet Oncol 2010, 11:962-972.
80. Sherman S.I., Wirth L.J., Droz J.P., et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008, 359:31-42.
81. Sherman S.I., Jarzab B., Cabanillas M.E., et al. A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J Clin Oncol 2011, 29. A5503.